• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

双氢青蒿素/哌喹和氯喹治疗和阻断传播对柬埔寨间日疟原虫疟疾的疗效。

Therapeutic and Transmission-Blocking 
Efficacy of Dihydroartemisinin/Piperaquine and Chloroquine against Plasmodium vivax Malaria, Cambodia.

出版信息

Emerg Infect Dis. 2018 Aug;24(8):1516-1519. doi: 10.3201/eid2408.170768. Epub 2018 Aug 17.

DOI:10.3201/eid2408.170768
PMID:29798745
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6056113/
Abstract

We assessed the efficacy of standard 3-day courses of chloroquine and dihydroartemisinin/piperaquine against Plasmodium vivax malaria. Compared with chloroquine, dihydroartemisinin/piperaquine was faster in clearing asexual P. vivax parasites and blocking human-to-mosquito transmission. This drug combination was also more effective in preventing potential recurrences for >2 months.

摘要

我们评估了标准的 3 天疗程氯喹和双氢青蒿素/哌喹治疗间日疟原虫疟疾的疗效。与氯喹相比，双氢青蒿素/哌喹能更快地清除无性期 vivax 疟原虫并阻断人传蚊。这种药物组合在预防潜在复发方面也更有效，超过 2 个月。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bec7/6056113/8a03a52a4b68/17-0768-F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bec7/6056113/da61a3ba968f/17-0768-F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bec7/6056113/8a03a52a4b68/17-0768-F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bec7/6056113/da61a3ba968f/17-0768-F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bec7/6056113/8a03a52a4b68/17-0768-F2.jpg

相似文献

1
Therapeutic and Transmission-Blocking 
Efficacy of Dihydroartemisinin/Piperaquine and Chloroquine against Plasmodium vivax Malaria, Cambodia.双氢青蒿素/哌喹和氯喹治疗和阻断传播对柬埔寨间日疟原虫疟疾的疗效。
Emerg Infect Dis. 2018 Aug;24(8):1516-1519. doi: 10.3201/eid2408.170768. Epub 2018 Aug 17.
2
A Randomized Comparison of Chloroquine Versus Dihydroartemisinin-Piperaquine for the Treatment of Plasmodium vivax Infection in Vietnam.越南氯喹与双氢青蒿素哌喹治疗间日疟原虫感染的随机对照比较
Am J Trop Med Hyg. 2016 Apr;94(4):879-885. doi: 10.4269/ajtmh.15-0740. Epub 2016 Feb 8.
3
Susceptibility of Plasmodium falciparum to artemisinins and Plasmodium vivax to chloroquine in Phuoc Chien Commune, Ninh Thuan Province, south-central Vietnam.越南中南部宁顺省福川乡恶性疟原虫对青蒿素类药物的敏感性和间日疟原虫对氯喹的敏感性。
Malar J. 2019 Jan 17;18(1):10. doi: 10.1186/s12936-019-2640-2.
4
Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial.双氢青蒿素-哌喹与氯喹治疗阿富汗间日疟的开放随机非劣效性试验。
Malar J. 2010 Apr 21;9:105. doi: 10.1186/1475-2875-9-105.
5
Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria.氯喹与双氢青蒿素-哌喹联合标准高剂量伯氨喹，分别治疗 7 天和 14 天，用于治疗间日疟原虫疟疾。
Clin Infect Dis. 2019 Apr 8;68(8):1311-1319. doi: 10.1093/cid/ciy735.
6
Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria in Papua New Guinea.青蒿琥酯-咯萘啶和双氢青蒿素-哌喹治疗巴布亚新几内亚无并发症疟疾的疗效。
Malar J. 2018 Oct 5;17(1):350. doi: 10.1186/s12936-018-2494-z.
7
Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial.双氢青蒿素-哌喹与氯喹治疗泰国间日疟原虫疟疾的随机对照试验。
Clin Infect Dis. 2011 Nov;53(10):977-84. doi: 10.1093/cid/cir631.
8
Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010.2008 年至 2010 年柬埔寨二氢青蒿素-哌喹治疗无并发症恶性疟原虫和间日疟原虫的疗效。
Antimicrob Agents Chemother. 2013 Feb;57(2):818-26. doi: 10.1128/AAC.00686-12. Epub 2012 Dec 3.
9
Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia.在埃塞俄比亚，青蒿琥酯-咯萘啶和双氢青蒿素-哌喹治疗无并发症恶性疟原虫和氯喹与双氢青蒿素-哌喹治疗无并发症间日疟原虫感染的疗效。
Malar J. 2022 Dec 1;21(1):359. doi: 10.1186/s12936-022-04350-z.
10
Efficacy of two versus three-day regimens of dihydroartemisinin-piperaquine for uncomplicated malaria in military personnel in northern Cambodia: an open-label randomized trial.二日和三日双氢青蒿素哌喹方案治疗柬埔寨北部军人无并发症疟疾的疗效：一项开放标签随机试验。
PLoS One. 2014 Mar 25;9(3):e93138. doi: 10.1371/journal.pone.0093138. eCollection 2014.

引用本文的文献

1
[Effect of low-dose primaquine treatment on Plasmodium vivax recurrence and transmission-blocking activity in southwest Ethiopia: a longitudinal cohort study.低剂量伯氨喹治疗对埃塞俄比亚西南部间日疟原虫复发及传播阻断活性的影响：一项纵向队列研究
Malar J. 2025 Apr 17;24(1):125. doi: 10.1186/s12936-025-05365-y.
2
Transmission-blocking activities of artesunate, chloroquine, and methylene blue on gametocytes.青蒿琥酯、氯喹和亚甲蓝对配子体的阻断作用。
Antimicrob Agents Chemother. 2024 Sep 4;68(9):e0085324. doi: 10.1128/aac.00853-24. Epub 2024 Jul 26.
3
Transmission-blocking activity of antimalarials for Plasmodium vivax malaria in Anopheles darlingi.

本文引用的文献

1
Plasmodium vivax Malaria in Cambodia.柬埔寨的间日疟原虫疟疾
Am J Trop Med Hyg. 2016 Dec 28;95(6 Suppl):97-107. doi: 10.4269/ajtmh.16-0208. Epub 2016 Oct 5.
2
Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial.双氢青蒿素哌喹对非洲疟疾患者再治疗的安全性和有效性：WANECAM随机试验的一项子研究
Lancet Infect Dis. 2016 Feb;16(2):189-98. doi: 10.1016/S1473-3099(15)00318-7. Epub 2015 Oct 23.
3
An innovative tool for moving malaria PCR detection of parasite reservoir into the field.
按蚊中抗疟原虫药物对间日疟原虫的阻断作用。
PLoS Negl Trop Dis. 2023 Jun 16;17(6):e0011425. doi: 10.1371/journal.pntd.0011425. eCollection 2023 Jun.
4
Therapeutic efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium vivax malaria in Seacha area, Arbaminch Zuria District, South West Ethiopia.二氢青蒿素-哌喹治疗埃塞俄比亚西南部 Arbaminch Zuria 区 Seacha 地区无并发症间日疟的疗效。
Malar J. 2022 Nov 27;21(1):351. doi: 10.1186/s12936-022-04380-7.
5
Chloroquine against malaria, cancers and viral diseases.氯喹用于治疗疟疾、癌症和病毒性疾病。
Drug Discov Today. 2020 Sep 16;25(11):2012-22. doi: 10.1016/j.drudis.2020.09.010.
6
Declining Burden of in a Population in Northwestern Thailand from 1995 to 2016 before Comprehensive Primaquine Prescription for Radical Cure.1995 年至 2016 年在全面普那喹处方根治前，泰国西北部人群中的负担下降。
Am J Trop Med Hyg. 2020 Jan;102(1):147-150. doi: 10.4269/ajtmh.19-0496.
7
Developments in Taste-Masking Techniques for Traditional Chinese Medicines.中药掩味技术的发展
Pharmaceutics. 2018 Sep 12;10(3):157. doi: 10.3390/pharmaceutics10030157.
一种创新工具，将疟疾 PCR 检测寄生虫库推向现场。
Malar J. 2013 Nov 9;12:405. doi: 10.1186/1475-2875-12-405.
4
G6PD deficiency in Plasmodium falciparum and Plasmodium vivax malaria-infected Cambodian patients.柬埔寨恶性疟原虫和间日疟原虫感染患者中的葡萄糖-6-磷酸脱氢酶缺乏症
Malar J. 2013 May 28;12:171. doi: 10.1186/1475-2875-12-171.
5
Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial.青蒿琥酯-咯萘啶和双氢青蒿素-哌喹治疗后疟疾传播：一项随机试验。
J Infect Dis. 2013 Jun 1;207(11):1637-45. doi: 10.1093/infdis/jit077. Epub 2013 Mar 6.
6
Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010.2008 年至 2010 年柬埔寨二氢青蒿素-哌喹治疗无并发症恶性疟原虫和间日疟原虫的疗效。
Antimicrob Agents Chemother. 2013 Feb;57(2):818-26. doi: 10.1128/AAC.00686-12. Epub 2012 Dec 3.
7
The global public health significance of Plasmodium vivax.间日疟原虫的全球公共卫生意义。
Adv Parasitol. 2012;80:1-111. doi: 10.1016/B978-0-12-397900-1.00001-3.
8
A long neglected world malaria map: Plasmodium vivax endemicity in 2010.一个长期被忽视的世界疟疾地图：2010 年间日疟原虫的流行情况。
PLoS Negl Trop Dis. 2012;6(9):e1814. doi: 10.1371/journal.pntd.0001814. Epub 2012 Sep 6.
9
Mosquito feeding assays to determine the infectiousness of naturally infected Plasmodium falciparum gametocyte carriers.蚊子喂食实验以确定自然感染疟原虫配子体携带者的感染性。
PLoS One. 2012;7(8):e42821. doi: 10.1371/journal.pone.0042821. Epub 2012 Aug 22.
10
Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria.以青蒿素为基础的联合疗法治疗无并发症间日疟原虫疟疾。
Cochrane Database Syst Rev. 2011 Jul 6(7):CD008492. doi: 10.1002/14651858.CD008492.pub2.